{"url_path":"/sec/xbio/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1534525/0001683168-26-003766-index.html","accession_number":"0001683168-26-003766","cik":"0001534525","ticker":"XBIO","issuer_name":"Xenetic Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1534525/0001683168-26-003766-index.html","primary_entity_key":"0001534525","primary_entity_name":"Xenetic Biosciences, Inc."},"word_count":102,"has_tables":true,"body_markdown":"**Item 9.01.**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n** **\n\n****\n\n**Exhibit No.**\n \n**Description**\n\n \n \n \n\n99.1\n \n[Press Release dated May 13, 2026 pertaining to the financial results of the Company for the three months ended March 31, 2026.](xenetic_ex9901.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n** **\n\n \n\n \n\n \n\n \n\n 2 \n\n \n\n \n\n****\n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**XENETIC BIOSCIENCES, INC.**\n\n \n \n \n\n \nBy:\n/s/ James Parslow                                        \n\nDate: May 13, 2026\nName:\nJames Parslow\n\n \nTitle:\nInterim Chief Executive Officer and Chief Financial Officer\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 3"}